
Jeffrey S Barrett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8347710/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of treatment regimen with moroctocog alfa (AFâ€CC) on bleeding rates in paediatric patients with severe haemophilia A. Haemophilia, 2020, 26, e232-e235.	2.1	0
2	Perspective on Data‣haring Requirements for the Necessary Evolution of Drug Development. Journal of Clinical Pharmacology, 2020, 60, 688-690.	2.0	2
3	Realâ€World Data: An Unrealized Opportunity in Global Health?. Clinical Pharmacology and Therapeutics, 2019, 106, 57-59.	4.7	7
4	A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis. European Journal of Rheumatology, 2019, 6, 23-28.	0.6	1
5	Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF C) in Subjects With Severe Hemophilia A. Clinical and Translational Science, 2018, 11, 283-288.	3.1	4
6	Clinical experience with moroctocog alfa (<scp>AF</scp> â€ <scp>CC</scp>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. Haemophilia, 2018, 24, 604-610.	2.1	5
7	A Pilot Doseâ€Finding Study of Etanercept in Rheumatoid Arthritis. Clinical and Translational Science, 2018, 11, 38-45.	3.1	3
8	The Path to Perfect Pediatric Posology — Drug Development in Pediatrics. Journal of Clinical Pharmacology, 2018, 58, S48-S57.	2.0	15
9	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
10	Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women. Clinical Pharmacology in Drug Development, 2018, 7, 920-926.	1.6	4
11	Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa. Clinical Pharmacology and Therapeutics, 2017, 102, 977-988.	4.7	20
12	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. Clinical Therapeutics, 2017, 39, 1313-1319.	2.5	4
13	Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 1052-1057.	3.4	10
14	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE, 2017, 12, e0175207.	2.5	92
15	Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. Clinical Therapeutics, 2016, 38, 936-944.	2.5	7
16	Population pharmacokinetic modelling of factor <scp>IX</scp> activity after administration of recombinant factor <scp>IX</scp> in patients with haemophilia B. Haemophilia, 2016, 22, e359-66.	2.1	10
17	Onceâ€weekly prophylactic treatment vs. onâ€demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia, 2016, 22, 381-388.	2.1	41
18	Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases. Clinical Pharmacology and Therapeutics, 2016, 100, 333-335.	4.7	2

JEFFREY S BARRETT

#	Article	IF	CITATIONS
19	Industry Perspective of Drug Development for Pregnant/Breastfeeding Women. Clinical Pharmacology and Therapeutics, 2016, 100, 19-21.	4.7	1
20	Assessment of relative bioavailability of two presentations of moroctocog alfa (AF C) in subjects with moderately severe or severe hemophilia A. Clinical Pharmacology in Drug Development, 2015, 4, 237-241.	1.6	5
21	Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics. Journal of Clinical Pharmacology, 2015, 55, S1-3.	2.0	1
22	Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis, 2015, 114, 676-684.	3.4	9
23	Steadyâ€ s tate pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. Clinical Pharmacology in Drug Development, 2014, 3, 235-241.	1.6	5
24	Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clinical Pharmacology in Drug Development, 2014, 3, 151-157.	1.6	19
25	Comparative Bioavailability Study of Single-Dose Film-Coated and Sugar-Coated Ethionamide Tablets in Healthy Volunteers. Clinical Therapeutics, 2014, 36, 982-987.	2.5	6
26	Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. Journal of Clinical Pharmacology, 2014, 54, 70-74.	2.0	13
27	Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Journal of Clinical Pharmacology, 2014, 54, 513-519.	2.0	9
28	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology, 2013, 69, 835-842.	1.9	9
29	Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1756-1762.	3.2	208
30	Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline. Antimicrobial Agents and Chemotherapy, 2012, 56, 1065-1072.	3.2	89
31	Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2012, 56, 130-136.	3.2	44
32	Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function. Journal of Clinical Pharmacology, 2012, 52, 1379-1387.	2.0	32
33	Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clinical Pharmacology in Drug Development, 2012, 1, 32-37.	1.6	34
34	Comparative Sirolimus Pharmacokinetics After Single-Dose Administration of Two Prototype 0.5-mg Tablets in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2012, 1, 52-6.	1.6	1
35	Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. European Journal of Clinical Pharmacology, 2012, 68, 589-597.	1.9	4
36	Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. Transplantation, 2011, 92, 303-310.	1.0	198

JEFFREY S BARRETT

#	Article	IF	CITATIONS
37	Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis. Journal of Clinical Pharmacology, 2011, 51, 864-875.	2.0	17
38	Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women. Antimicrobial Agents and Chemotherapy, 2011, 55, 5200-5204.	3.2	41
39	Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2010, 54, 5180-5186.	3.2	35
40	Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2007, 51, 4085-4089.	3.2	33
41	Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia, 2005, 11, 571-582.	2.1	60
42	Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. Journal of Clinical Oncology, 2004, 22, 2336-2347.	1.6	506
43	Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin. Journal of Clinical Pharmacology, 2004, 44, 543-550.	2.0	38
44	Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. Journal of Clinical Pharmacology, 2004, 44, 873-880.	2.0	54
45	Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin. Journal of Clinical Pharmacology, 2004, 44, 1244-1251.	2.0	34
46	Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. Journal of Clinical Pharmacology, 2001, 41, 1206-1214.	2.0	124
47	Evaluating Possible Pharmacokinetic Interactions between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients with Various Degrees of Renal Impairment. Journal of Clinical Pharmacology, 2001, 41, 979-986.	2.0	8
48	Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery. Journal of Clinical Pharmacology, 1999, 39, 729-737.	2.0	22
49	Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two tage Pharmacokinetic Analysis. Journal of Clinical Pharmacology, 1997, 37, 610-617.	2.0	22